BioMarin and Ascendis settle patent disputes over Yuviwel
Shares of drugmaker BioMarin Pharmaceutical $BMRN.O rise 5.9% to $68.48 premarket
BioMarin and Ascendis Pharma $ASND.O settle all patent disputes related to Ascendis' growth disorder drug Yuviwel
Ascendis to pay BioMarin a 20% royalty on U.S. Yuviwel sales, starting from the drug's first commercial sale
Ascendis also agrees to pay BioMarin an 18% royalty on Yuviwel sales in the EU, Brazil and South Korea until May 2030
Yuviwel is Ascendis' once-weekly injectable treatment for children aged 2 years and older with achondroplasia, the most common form of dwarfism, and it received U.S. FDA accelerated approval on Feb
The legal dispute began in 2025 when BioMarin filed an ITC complaint alleging that Ascendis' drug infringes its patents
BMRN•
